After Burn

The dosage of Lidocaine Hydrochloride Anhydrous varies significantly based on the intended use, the area to be anesthetized, and the patient's physical condition. According to standard clinical guidelines:

• Local Infiltration: For healthy adults, the maximum individual dose should not exceed 4.5 mg/kg of body weight, with a total maximum dose of 300 mg. If administered with epinephrine (which slows absorption), the maximum dose may be increased to 7 mg/kg (up to 500 mg).
• Intravenous Antiarrhythmic Loading Dose: Typically, an initial bolus of 1 to 1.5 mg/kg is administered. If the arrhythmia persists, additional boluses of 0.5 to 0.75 mg/kg may be given every 5 to 10 minutes, up to a total of 3 mg/kg.
• Maintenance Infusion: For continuous cardiac stabilization, a rate of 1 to 4 mg per minute is standard following the loading dose.
• Topical Application: For the 5% transdermal patch, no more than three patches should be applied at once for a maximum of 12 hours within a 24-hour period.

Pediatric dosing must be calculated with extreme caution to avoid systemic toxicity.

• General Guidelines: Doses are strictly weight-based. For infiltration, the dose should generally not exceed 3 to 4.5 mg/kg.
• Emergency Cardiac Use: The standard pediatric IV/IO dose is 1 mg/kg as a loading dose, followed by an infusion of 20 to 50 mcg/kg/min.
• Safety Note: Lidocaine should not be used in children under the age of 2 for teething pain or oral discomfort due to the risk of seizures and severe cardiac injury.

Renal Impairment

While the kidneys only excrete a small portion of lidocaine unchanged, metabolites (MEGX and GX) can accumulate in patients with severe renal failure. Healthcare providers may monitor these patients closely for signs of CNS toxicity during prolonged infusions.

Hepatic Impairment

Because lidocaine is primarily metabolized by the liver, patients with hepatic cirrhosis or significant liver dysfunction require a dose reduction of 50% or more. Failure to adjust the dose in these patients significantly increases the risk of Local Anesthetic Systemic Toxicity (LAST).

Elderly Patients

Geriatric patients often have reduced cardiac output and hepatic blood flow. Consequently, lower doses and slower titration are recommended to prevent accumulation and toxicity.

• Injections: These are always administered by a trained healthcare professional in a clinical setting where monitoring equipment is available.
• Topical Patches: Apply to clean, dry, intact skin. Do not apply to broken or infected skin. Wash hands immediately after application or removal.
• Viscous Lidocaine: If using for oral pain, do not eat or drink for at least 60 minutes after use, as the numbing effect can impair swallowing and increase the risk of choking (aspiration).
• Storage: Store at room temperature (20°C to 25°C / 68°F to 77°F). Protect from light and do not freeze.

In a clinical setting (injections/infusions), missed doses are unlikely as the medication is administered by staff. For at-home topical use, if you miss a dose, apply it as soon as you remember. If it is almost time for the next application, skip the missed dose. Do not double the dose to catch up.

Lidocaine overdose leads to a condition known as Local Anesthetic Systemic Toxicity (LAST).

• Early Signs: Numbness of the tongue, metallic taste, lightheadedness, and tinnitus (ringing in the ears).
• Progressive Signs: Muscle twitching, tremors, and visual disturbances.
• Severe Signs: Seizures, respiratory arrest, and cardiovascular collapse (cardiac arrest).
• Emergency Action: If an overdose is suspected, immediate medical intervention is required. Treatment typically involves airway management, seizure control, and the administration of intravenous lipid emulsion (Intralipid) to 'soak up' the excess lidocaine from the bloodstream.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or application frequency without explicit medical guidance.

Side effects of Lidocaine Hydrochloride Anhydrous often depend on the route of administration. For topical or local applications, common reactions include:

• Local Erythema: Redness at the site of application or injection.
• Edema: Mild swelling of the treated tissue.
• Altered Sensation: A feeling of numbness, tingling ('pins and needles'), or coldness in the area that may persist for several hours after the procedure.
• Pallor: Blanched or pale skin at the injection site, particularly if epinephrine was used.

When lidocaine enters the systemic circulation in moderate amounts, patients may experience:

• Dizziness or Lightheadedness: A feeling of instability or spinning.
• Nausea: Occasional stomach upset, particularly during IV administration.
• Tinnitus: A ringing or buzzing sound in the ears.
• Blurred Vision: Temporary difficulty focusing or 'double vision.'
• Drowsiness: A significant feeling of sleepiness or sedation.

• Euphoria or Hallucinations: Unusual changes in mood or perception.
• Bradycardia: An abnormally slow heart rate.
• Hypotension: Low blood pressure that may cause fainting.
• Methemoglobinemia: A rare blood disorder where the hemoglobin cannot effectively carry oxygen, resulting in bluish skin (cyanosis), headache, and fatigue.

> Warning: Stop using Lidocaine Hydrochloride Anhydrous and call your doctor immediately or seek emergency care if you experience any of the following:

• Anaphylaxis: Signs include hives, severe itching, swelling of the face, lips, or tongue, and difficulty breathing. This is a life-threatening allergic reaction.
• Seizures: Involuntary muscle contractions or loss of consciousness, often preceded by twitching or a metallic taste.
• Respiratory Depression: Dangerously slow or shallow breathing.
• Cardiac Arrhythmias: Feeling like your heart is skipping beats, racing, or pounding, which can progress to cardiac arrest.
• Severe CNS Toxicity: Extreme confusion, agitation, or sudden unresponsiveness.

Lidocaine is generally intended for acute, short-term use. However, prolonged or repeated use can lead to:

• Contact Dermatitis: Chronic skin irritation or allergic sensitization to the amide class of anesthetics.
• Tissue Damage: Repeated injections into the same area can cause localized tissue breakdown or scarring.
• Nerve Injury: While rare, direct needle trauma or high concentrations of anesthetic near a nerve can lead to prolonged or permanent paresthesia (numbness).

While Lidocaine Hydrochloride Anhydrous does not carry a universal 'Black Box Warning' for all forms, the FDA has issued specific Boxed Warnings for certain lidocaine products, particularly Viscous Lidocaine 2%:

• Pediatric Safety Warning: Viscous lidocaine should not be used to treat teething pain in infants and children. Improper use has resulted in seizures, severe brain injury, and death. Healthcare providers should strictly adhere to dosing limits and avoid use in this population unless absolutely necessary for other medical reasons.

Report any unusual symptoms or persistent side effects to your healthcare provider immediately. Modern monitoring techniques in clinical settings are designed to catch these effects early, but patient vigilance is crucial for at-home applications.

Lidocaine Hydrochloride Anhydrous is a potent medication that requires careful administration. The most critical safety concern is avoiding systemic toxicity, which occurs when blood levels of lidocaine rise too high. This can happen through accidental injection into a blood vessel, excessive dosing, or impaired metabolism by the liver. Patients must inform their providers of all underlying health conditions, especially those affecting the heart, liver, or kidneys.

As noted in the side effects section, the FDA emphasizes a specific warning for Viscous Lidocaine: It is strictly contraindicated for teething pain in infants. For other forms of lidocaine, while no formal Black Box Warning exists for general adult use, the risk of Local Anesthetic Systemic Toxicity (LAST) is treated with the highest level of clinical precaution.

• Allergic Reactions: While amide-type allergies are rare, they can occur. Cross-sensitivity between lidocaine and other amides (like bupivacaine or ropivacaine) is possible. Patients with a history of sensitivity to 'caine' anesthetics must be evaluated by an allergist.
• Cardiovascular Disease: Lidocaine is a potent depressant of cardiac conduction. Patients with pre-existing heart block, severe bradycardia, or heart failure are at a significantly higher risk for further cardiac depression or arrest.
• Hepatic Disease: Since the liver clears 90% of lidocaine, any degree of liver failure increases the risk of toxic accumulation. Monitoring of liver function tests (LFTs) is essential for patients receiving prolonged infusions.
• CNS Disorders: Patients with a history of epilepsy or other seizure disorders may have a lower threshold for lidocaine-induced CNS toxicity.
• Methemoglobinemia Risk: Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or those taking other oxidizing drugs (like sulfonamides) are at higher risk for this rare but serious blood disorder.

Patients receiving Lidocaine Hydrochloride Anhydrous via injection or infusion require continuous monitoring, including:

• Electrocardiogram (ECG): To monitor for heart rate changes or rhythm disturbances.
• Blood Pressure: To detect hypotension.
• Pulse Oximetry: To ensure adequate oxygenation and detect respiratory depression.
• Serum Lidocaine Levels: In long-term infusions (over 24 hours), drug levels may be measured to ensure they stay within the therapeutic range (1.5 to 5.0 mcg/mL).

Lidocaine can cause drowsiness, dizziness, and blurred vision. Patients should not drive or operate heavy machinery until the effects of the anesthetic have completely worn off and they feel fully alert. This is especially important following major nerve blocks or epidurals, where motor function may also be temporarily impaired.

Alcohol should be avoided immediately before and after the administration of lidocaine. Alcohol can enhance the central nervous system depressant effects of lidocaine, increasing the risk of respiratory depression and severe sedation.

For most local procedures, lidocaine is a single-dose medication. For IV infusions, the drug is typically tapered slowly to monitor for the return of arrhythmias. There is no 'withdrawal syndrome' associated with lidocaine, but the underlying condition (such as pain or arrhythmia) may return once the drug is stopped.

> Important: Discuss all your medical conditions, including any history of heart, liver, or kidney disease, with your healthcare provider before starting Lidocaine Hydrochloride Anhydrous.

Lidocaine Hydrochloride Anhydrous should never be used in combination with certain medications due to the risk of life-threatening interactions:

• Class Ib Antiarrhythmics (e.g., Mexiletine): Using two drugs from the same class results in additive toxicity, significantly increasing the risk of cardiac arrest and seizures.
• Buprenorphine: When used systemically, this combination can lead to profound respiratory depression and CNS collapse.

• Beta-Blockers (e.g., Propranolol, Metoprolol): These drugs reduce cardiac output and hepatic blood flow. This slows the clearance of lidocaine from the body, potentially leading to toxic levels. Healthcare providers may need to reduce the lidocaine dose.
• Cimetidine: This H2-blocker inhibits the CYP1A2 and CYP3A4 enzymes responsible for lidocaine metabolism. Concurrent use can increase lidocaine blood levels by up to 30%.
• Amiodarone: This antiarrhythmic can have additive effects on the heart's conduction system, increasing the risk of severe bradycardia or heart block.

• Antipsychotics (e.g., Pimozide, Quetiapine): Some antipsychotics can prolong the QT interval or lower the seizure threshold, making the CNS and cardiac effects of lidocaine more dangerous.
• Neuromuscular Blockers (e.g., Succinylcholine): Lidocaine may prolong the muscle-paralyzing effects of these drugs used during surgery.
• Local Anesthetics: Using multiple different local anesthetics (e.g., lidocaine plus articaine) can lead to additive systemic toxicity.

• Grapefruit Juice: While primarily affecting oral medications, grapefruit juice inhibits CYP3A4. For patients using lidocaine over long periods (e.g., patches), excessive grapefruit consumption could theoretically slow metabolism, though the clinical impact is usually minimal.
• High-Fat Meals: Do not affect lidocaine injections or patches, but may affect the absorption of oral lidocaine formulations (rarely used).

• St. John’s Wort: This herb induces CYP3A4 enzymes, which may speed up the metabolism of lidocaine and reduce its effectiveness.
• Kava and Valerian: These supplements have sedative properties and may enhance the CNS-depressant effects of lidocaine, leading to excessive drowsiness.

• Creatine Phosphokinase (CPK): Intramuscular injection of lidocaine may increase CPK levels, which could interfere with the diagnosis of an acute myocardial infarction (heart attack).
• Diagnostic Skin Tests: Topical lidocaine may interfere with the results of skin allergen testing by suppressing the inflammatory response.

For each major interaction, the primary mechanism is usually enzyme inhibition (slowing metabolism) or pharmacodynamic synergism (doubling down on the same side effect). Management typically involves dose adjustment or choosing an alternative anesthetic.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.

There are several conditions where Lidocaine Hydrochloride Anhydrous must NEVER be used because the risks far outweigh any potential benefits:

1. 1Hypersensitivity to Amide Anesthetics: If a patient has a known allergy to lidocaine, bupivacaine, mepivacaine, or ropivacaine, administration can cause fatal anaphylaxis. This is due to the shared chemical structure of these agents.
2. 2Stokes-Adams Syndrome: This condition involves sudden attacks of fainting due to heart block. Lidocaine can further suppress the heart's natural pacemakers, leading to complete cardiac standstill.
3. 3Severe Sinoatrial, Atrioventricular, or Intraventricular Heart Block: In the absence of a functional artificial pacemaker, lidocaine will block the remaining electrical 'escape' rhythms, preventing the heart from beating.
4. 4Wolff-Parkinson-White (WPW) Syndrome: In patients with WPW and atrial fibrillation, lidocaine can paradoxically increase the heart rate to dangerous levels by favoring conduction through an accessory pathway.

In these scenarios, a healthcare provider will perform a careful risk-benefit analysis:

• Severe Hypovolemia (Low Blood Volume): Lidocaine-induced vasodilation or cardiac depression can cause a catastrophic drop in blood pressure.
• Congestive Heart Failure: Reduced cardiac output leads to poor liver perfusion and a high risk of drug toxicity.
• Myasthenia Gravis: Patients with this neuromuscular disorder may be more sensitive to the muscle-relaxing effects of local anesthetics.

Patients should be aware that Lidocaine Hydrochloride Anhydrous is an amide. It does not typically cross-react with ester anesthetics (like benzocaine or procaine). However, many local anesthetic vials contain a preservative called methylparaben, which is chemically similar to esters. A patient might react to the preservative rather than the lidocaine itself. In such cases, 'preservative-free' lidocaine may be required.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of 'fainting spells' or heart rhythm issues, before prescribing or administering Lidocaine Hydrochloride Anhydrous.

Lidocaine Hydrochloride Anhydrous is classified as FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.

• Trimester Considerations: Lidocaine is generally considered safe for use during all trimesters for necessary medical procedures. It is the preferred local anesthetic for dental work and minor surgeries during pregnancy.
• Labor and Delivery: Lidocaine readily crosses the placenta. If used for epidural or paracervical blocks in high doses, it can cause 'fetal bradycardia' (slowed fetal heart rate). Continuous fetal monitoring is required during these procedures.

Lidocaine is excreted into breast milk in very small amounts. The American Academy of Pediatrics considers lidocaine to be compatible with breastfeeding. The amount an infant would ingest via milk after a mother receives a standard local anesthetic dose is considered clinically insignificant. No special precautions are typically needed other than monitoring the infant for rare signs of drowsiness.

Lidocaine is approved for pediatric use, but with strict limitations.

• Dosing: Must be strictly calculated by weight (mg/kg).
• Risks: Children are at a higher risk for systemic toxicity (LAST) because they have a smaller volume of distribution and potentially immature metabolic pathways.
• Contraindications: As previously noted, the FDA warns against the use of viscous lidocaine for teething pain in children under age 2 due to the risk of fatal seizures.

Patients over the age of 65 require individualized dosing.

• Pharmacokinetics: Age-related declines in hepatic blood flow and renal clearance mean lidocaine stays in the system longer.
• Fall Risk: The dizziness and potential motor block associated with lidocaine increase the risk of falls in the elderly.
• Polypharmacy: Older adults are more likely to be taking beta-blockers or antiarrhythmics, increasing the likelihood of drug-drug interactions.

While the parent drug is metabolized by the liver, its metabolites (GX and MEGX) are cleared by the kidneys. In patients with a GFR (Glomerular Filtration Rate) below 30 mL/min, these metabolites can accumulate, potentially causing CNS toxicity (confusion, tremors). Dose adjustments are usually not needed for single doses, but are critical for infusions lasting longer than 24 hours.

This is the most critical population for lidocaine safety. In patients with Child-Pugh Class B or C hepatic impairment, the half-life of lidocaine can increase from 1.5 hours to over 5 hours. Initial doses should be reduced by at least 50%, and maintenance infusions must be monitored with frequent serum drug level checks.

> Important: Special populations require individualized medical assessment and often require lower starting doses to ensure safety.

Lidocaine Hydrochloride Anhydrous is a potent inhibitor of voltage-gated sodium channels (specifically the NaV1.5 subtype in the heart and various subtypes in peripheral nerves). It binds to the S6 segment of domain IV on the alpha-subunit of the sodium channel. By stabilizing the channel in the inactivated state, it prevents the rapid influx of sodium ions required for the depolarization of the cell membrane. In nerves, this halts the propagation of pain signals. In the heart, it suppresses phase 0 of the cardiac action potential, reducing the slope of spontaneous diastolic depolarization in the ventricles.

• Onset of Action: Very rapid. For infiltration, onset is within 1 to 5 minutes. For IV antiarrhythmic use, the effect is almost immediate.
• Duration of Effect: Moderate. Without epinephrine, the effect lasts 30 to 120 minutes. With epinephrine, the duration can be extended to 2 to 4 hours.
• Tolerance: Tachyphylaxis (a rapid decrease in response to repeated doses) can occur with lidocaine, particularly in the setting of localized acidosis (e.g., infected tissue), which prevents the drug from entering the nerve cell.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV); 35% (Oral - high first-pass); 3% (Topical) |

| Protein Binding | 60% to 80% (primarily to alpha-1-acid glycoprotein) |

| Half-life | 1.5 to 2 hours (Adults); up to 5+ hours (Hepatic failure) |

| Tmax | 0.5 to 2 hours (Topical); Immediate (IV) |

| Metabolism | Hepatic (CYP1A2, CYP3A4) to MEGX and GX |

| Excretion | Renal (<10% unchanged, 90% as metabolites) |

• Molecular Formula: C14H22N2O · HCl
• Molecular Weight: 270.8 g/mol (Anhydrous)
• Solubility: Very soluble in water and alcohol.
• Structure: An aminoethylamide derivative. It consists of a lipophilic aromatic ring linked to a hydrophilic tertiary amine by an amide bond.

Lidocaine is classified as an Amide-type Local Anesthetic and a Vaughan Williams Class Ib Antiarrhythmic. It is related to other amides like bupivacaine and mepivacaine, but differs significantly from ester-type anesthetics like cocaine or benzocaine.